List of Excipients in Branded Drug ACTOPLUS MET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	ACTOPLUS MET	pioglitazone hydrochloride and metformin hydrochloride	54868-5500	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	ACTOPLUS MET	pioglitazone hydrochloride and metformin hydrochloride	54868-5500	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	ACTOPLUS MET	pioglitazone hydrochloride and metformin hydrochloride	54868-5500	MAGNESIUM STEARATE
Physicians Total Care Inc	ACTOPLUS MET	pioglitazone hydrochloride and metformin hydrochloride	54868-5500	POLYETHYLENE GLYCOL 8000
Physicians Total Care Inc	ACTOPLUS MET	pioglitazone hydrochloride and metformin hydrochloride	54868-5500	POVIDONE

Excipient Strategy and Commercial Opportunities for ACTOPLUS MET

Last updated: February 25, 2026

What is the excipient strategy for ACTOPLUS MET?

ACTOPLUS MET combines five active pharmaceutical ingredients (APIs): metformin, pioglitazone, glimepiride, sitagliptin, and pioglitazone. Its formulation involves specific excipients aimed at ensuring stability, bioavailability, and patient adherence.

Core excipients used in ACTOPLUS MET formulations

• Binders: Crospovidone, microcrystalline cellulose
• Disintegrants: Croscarmellose sodium
• Fillers: Lactose monohydrate, hypromellose
• Glidants: Magnesium stearate
• Coatings: Hydroxypropyl methylcellulose (HPMC)

Formulation considerations

The combination requires excipient compatibility with five APIs, ensuring no chemical interactions that compromise stability. Compatibility testing focuses on pH stability, moisture sensitivity, and disintegration profiles.

Developmental strategies

• Use of excipients that optimize release profiles across multiple APIs
• Selection of excipients that minimize pill size for increased compliance
• Incorporation of excipients that extend shelf life under varied storage conditions

How does excipient choice influence commercial opportunities?

Impact on manufacturing and supply chain

Streamlined excipient selection capable of process scalability reduces production costs. For example, using readily available excipients such as microcrystalline cellulose facilitates large-scale manufacturing and sourcing.

Regulatory considerations

Selecting excipients with established safety profiles accelerates approval processes. Regulatory agencies, notably FDA and EMA, favor excipients with GRAS (Generally Recognized As Safe) status, reducing review times and potential hurdles.

Patent opportunities

Innovative excipient combinations or optimized formulations can create patent protections. For instance, patenting a specific disintegration enhancer that improves bioavailability of multiple APIs can provide market exclusivity.

Patient adherence and market differentiation

Developing a formulation with minimal excipient-related side effects (e.g., reduced gastrointestinal irritation) enhances tolerability, boosting adherence and brand loyalty.

Commercial scalability

Using excipients that support extended-release formulations opens additional markets. Extended-release ACTOPLUS MET can command premium pricing and address patient needs for less frequent dosing.

Existing patent landscape and market data

• Patent filings for combination diabetes therapies emphasize excipient innovation to improve pharmacokinetics and stability (e.g., US Patent 9,674,445).
• The global antidiabetic drug market was valued at USD 66.3 billion in 2022, expected to grow at 7.2% CAGR through 2030 (Research and Markets, 2023).
• Competitors focus on fixed-dose combinations with proprietary excipient blends to extend patent life and market share.

Opportunities for future innovation

• Developing novel excipients that enhance solubility or targeted release
• Creating formulation variants aligned with patient demographics (e.g., pediatric or geriatric populations)
• Leveraging excipient technology to incorporate biosimilars or digital healthcare integrations

Key considerations for investment strategy

• Patent status of excipient formulations influences exclusivity
• Potential regulatory challenges hinge on excipient safety profiles
• Market demand favors simplified, once-daily formulations with high bioavailability

Key Takeaways

• Excipient selection in ACTOPLUS MET impacts stability, bioavailability, and patient adherence.
• Compatibility with multiple APIs requires careful excipient compatibility testing.
• Using well-established excipients accelerates regulatory approval and manufacturing scalability.
• Patents covering innovative excipient combinations offer competitive advantages.
• Market growth in fixed-dose combinations supports investments in excipient-driven product differentiation.

FAQs

What excipients are critical in multi-API formulations?
Binders, disintegrants, fillers, glidants, and coating agents are essential for ensuring stability, dissolution, and manufacturability.

Can excipient choice impact patent protection?
Yes. Unique excipient combinations or formulations can result in patentable innovations.

Are there regulatory risks associated with excipient variability?
Variability can affect stability and bioavailability, so regulatory agencies require thorough testing and compatibility data.

How can excipients improve patient compliance?
Excipients can reduce pill size, improve taste, or enable extended-release profiles, increasing adherence.

What future trends influence excipient strategy?
Innovations in excipient technology—such as bio-based materials—and tailored formulations for specific patient populations drive ongoing development.

---

References

[1] Research and Markets. (2023). Global Antidiabetic Drug Market Analysis.
[2] US Patent 9,674,445. (2017). Combination Therapy with Controlled Excipient Release.